Related references
Note: Only part of the references are listed.Weighted false discovery rate controlling procedures for clinical trials
Yoav Benjamini et al.
BIOSTATISTICS (2017)
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer
Yohei Masugi et al.
GUT (2017)
Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system
Kelly A. Schats et al.
HISTOPATHOLOGY (2017)
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Patricia Gaule et al.
JAMA ONCOLOGY (2017)
Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection
Shohei Eto et al.
GASTRIC CANCER (2016)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Woo Young Sun et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Christine Boeger et al.
ONCOTARGET (2016)
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Sarah Derks et al.
ONCOTARGET (2016)
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Lei Guo et al.
SPRINGERPLUS (2016)
CD8-positive T-cell lymphoproliferative disorder associated with Epstein-Barr virus-infected B-cells in a rheumatoid arthritis patient under methotrexate treatment
Hitoshi Koji et al.
MODERN RHEUMATOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
Francois Bertucci et al.
ONCOTARGET (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
Mark Ayers et al.
Journal for ImmunoTherapy of Cancer (2015)
Anti program death-1/anti program death-ligand 1 in digestive cancers
Eleonore de Guillebon et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2015)
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters
Anita Feichtenbeiner et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Charles G. Drake et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Raoul A. Droeser et al.
EUROPEAN JOURNAL OF CANCER (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
7th Edition of the AJCC Cancer Staging Manual: Stomach
Kay Washington
ANNALS OF SURGICAL ONCOLOGY (2010)
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
Josef Rueschoff et al.
VIRCHOWS ARCHIV (2010)
Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
H. E. Lee et al.
BRITISH JOURNAL OF CANCER (2008)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Association of virus infected-T cell in severe hepatitis caused by primary Epstein-Barr virus infection
S Hara et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
